Enerzair® Breezhaler® plus sensor is the first asthma medication to be co-packaged and co-prescribed with a digital health platform MADISON, Wis.--(BUSINESS WIRE)--Propeller Health today announced a ...

Patients in Japan using Enerzair® and Atectura® Breezhaler® to treat uncontrolled asthma will now have access to Propeller’s digital health platform through their clinician MADISON, Wis.--(BUSINESS ...

European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with ...

Novartis NVS announced that the European Commission (EC) has approved Enerzair Breezhaler (QVM149; indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]).It was granted ...

Novartis and respiratory health company Propeller Health, a ResMed subsidiary, have teamed up to co-package the latter’s digital health platform with the pharma giant’s new asthma medication Enerzair ...

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Enerzair Breezhaler, the first triple-combination asthma therapy that ...

The European Commission approves Novartis' (NVS-0.4%) once-daily Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate [IND/GLY/MF]) as a maintenance treatment of ...

Taiwan's economy is expected to grow faster in 2025 than previously forecast, the statistics agency said on Friday, as the island continues to reap the benefits of strong demand for tech and ...

The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...

A phase 3 trial of Novartis’ QMF149 in patients with uncontrolled asthma has met its primary endpoint. Novartis showed the drug combination is better at improving lung function than an inhaled ...